Corcept Therapeutics Inc.

CORT's P/E of 118.5 is strikingly elevated for a pharmaceutical company, reflecting either exceptional growth expectations or significant valuation risk. Trading 65.6 on the RSI suggests overbought conditions, yet the stock sits below its 52-week high, indicating restraint despite momentum. The 13.64% short interest is substantial but not extreme, hinting that skeptics have room to accumulate. For a $5.6B biotech player, this valuation multiple demands consistent blockbuster performance and pipeline success to justify the premium. The technical setup presents conflicting signals—overbought momentum fighting against missed highs—creating potential squeeze or pullback risk.